RSS   Newsletter   Contact   Advertise with us

Zentalis Pharmaceuticals to get $165.2 million from initial public offering

Share on Twitter Share on LinkedIn
Christian Fernsby ▼ | April 3, 2020
Zentalis Pharmaceuticals announced the pricing of its initial public offering of 9,180,000 shares of common stock at a public offering price of $18.00 per share, for total gross proceeds of approximately $165.2 million, before deducting underwriting discounts and commissions and offering expenses payable by Zentalis.
Zentalis Pharmaceuticals
IPO   Zentalis Pharmaceuticals
All of the common stock is being offered by Zentalis.

Topics: Zentalis Pharmaceuticals

The offering is expected to close on April 7, 2020, subject to customary closing conditions.

In addition, Zentalis has granted the underwriters a 30-day option to purchase up to an additional 1,377,000 shares of its common stock at the initial public offering price less the underwriting discounts and commissions.

Zentalis’ common stock is expected to begin trading on the Nasdaq Global Market on April 3, 2020, under the ticker symbol “ZNTL.”